Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: grosskurth se. Signal Transduct Target Ther. 2022 Apr 1;7(1):110. doi: 10.1038/s41392-022-00958-4. Signal Transduct Target Ther. 2022. PMID: 35365596 Free PMC article. No abstract available.
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: grosskurth se. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. Signal Transduct Target Ther. 2022. PMID: 35185150 Free PMC article.
Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
Vasanthakumar A, Davis JW, Idler K, Waring JF, Asque E, Riley-Gillis B, Grosskurth S, Srivastava G, Kim S, Nho K, Nudelman KNH, Faber K, Sun Y, Foroud TM, Estrada K, Apostolova LG, Li QS, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Vasanthakumar A, et al. Clin Epigenetics. 2020 Jun 15;12(1):84. doi: 10.1186/s13148-020-00864-y. Clin Epigenetics. 2020. PMID: 32539856 Free PMC article.
Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions.
Sieberts SK, Perumal TM, Carrasquillo MM, Allen M, Reddy JS, Hoffman GE, Dang KK, Calley J, Ebert PJ, Eddy J, Wang X, Greenwood AK, Mostafavi S; CommonMind Consortium (CMC); The AMP-AD Consortium; Omberg L, Peters MA, Logsdon BA, De Jager PL, Ertekin-Taner N, Mangravite LM. Sieberts SK, et al. Sci Data. 2020 Oct 12;7(1):340. doi: 10.1038/s41597-020-00642-8. Sci Data. 2020. PMID: 33046718 Free PMC article.
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E, Mullins S, Watkins A, Williams GS, Koopmann JO, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, Wilkinson RW. Poon E, et al. Among authors: grosskurth se. J Immunother Cancer. 2017 Aug 15;5(1):63. doi: 10.1186/s40425-017-0268-8. J Immunother Cancer. 2017. PMID: 28807001 Free PMC article.
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA. Kirschner AN, et al. Among authors: grosskurth se. J Natl Cancer Inst. 2014 Dec 13;107(2):dju407. doi: 10.1093/jnci/dju407. Print 2015 Feb. J Natl Cancer Inst. 2014. PMID: 25505253 Free PMC article.
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, Lamb ML, Lawson D, Dry JR, Lyne PD, Tate EW, Zinda M, Mikule K, Fawell SE, Reimer C, Chen H. Wang Z, et al. Among authors: grosskurth se. Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8. Cancer Res. 2018. PMID: 30297535 Free article.
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. Scarborough HA, et al. Among authors: grosskurth se. Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23. Clin Cancer Res. 2017. PMID: 27663586 Free PMC article.
20 results